MedWatch

"..to take it to the market takes terrific people"

The new CEO of Fluxome, Angela Tsetsis, wants to use her many years of experience specifically to improve the commercial aspects of the company.

Foto: Fluxome/PR

The Danish biotech company Fluxome has just hired Angela Tsetsis as its new CEO. The American has been with the biotech company Martek for the last 19 years, and played a huge part in the commercialization process that lead to the company being bought by the Dutch food supplement company DSM.

Earlier this year Fluxome had the food supplement pill, Fluxome Resveratrol, approved in the EU. The pill is also known as the red wine-pill, because the antioxidant resveratrol is the substance from red wine known for being beneficial to our health.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

KU søger chef til nyt life science-program

Københavns Universitet har indledt jagten på den programdirektør, der skal stå i spidsen for innovationsprogrammet Spark Denmark, som Novo Nordisk Fonden forleden kastede 44 mio. kr. efter for at bringe flere akademiske projekter indenfor farma, medico, sundhedsteknologi og industriel biotek til markedet.

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier